Market revenue in 2023 | USD 237.9 million |
Market revenue in 2030 | USD 525.4 million |
Growth rate | 12% (CAGR from 2023 to 2030) |
Largest segment | Alzheimer's disease |
Fastest growing segment | Alzheimer's Disease |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder |
Key market players worldwide | Qiagen NV, Abbott Laboratories, Merck & Co Inc, Johnson & Johnson, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Sysmex Corp, Merck KGaA, Roche Holding AG, Nimble Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunoassay for neurological biomarkers market will help companies and investors design strategic landscapes.
Alzheimer's disease was the largest segment with a revenue share of 35.94% in 2023. Horizon Databook has segmented the Italy immunoassay for neurological biomarkers market based on alzheimer's disease, parkinson's disease, multiple sclerosis, autism spectrum disorder covering the revenue growth of each sub-segment from 2018 to 2030.
A wide network of manufacturers & distributors in this region is likely to provide a potential growth platform for this market. R&D activities are also expected to increase in Italy due to various funds & grants offered by government & nongovernment organizations for basic research.
For instance, the country has launched a pioneering program to identify people at a high risk of Alzheimer’s disease. The project aims to facilitate early diagnosis and treatment of the disease. Across Europe, the uptake of neurological biomarker testing technologies considerably varies.
Italy predominantly performs in-house biomarker testing. Moreover, the Italian government is focusing on increasing the adoption of biomarker testing for neurological diseases for early identification. Better diagnosis of diseases is expected to improve healthcare services in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy immunoassay for neurological biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into Italy immunoassay for neurological biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account